trending Market Intelligence /marketintelligence/en/news-insights/trending/ibJx_A0zk1NSRCGgSdCVBg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Novo Nordisk shareholders claim 11.79B kroner in lawsuit against company

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Novo Nordisk shareholders claim 11.79B kroner in lawsuit against company

Novo Nordisk A/S said a number of its shareholders have filed a lawsuit against the company in Denmark alleging it issued misleading statements about the sales of its insulin products in the U.S.

The shareholders, based on their trading and holding of shares between Feb. 3, 2015, and Feb. 2, 2017, have made a claim of 11.79 billion Danish kroner in the lawsuit. They also blame Novo for not disclosing appropriate information regarding the sales.

The Danish pharmaceutical giant dismissed the allegation and said it will defend the company in this matter.

A similar lawsuit was filed on behalf of all purchasers of Novo's American depositary receipts in the U.S. in 2017.

As of Aug. 15, US$1 was equivalent to 6.72 Danish kroner.